Screener
Royalty Pharma RPRX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
FAQ
- What is Royalty Pharma's net income?
- Royalty Pharma (RPRX) reported net income of $17.88M in Q2 2026.
- How has Royalty Pharma's net income changed year-over-year?
- Royalty Pharma's net income decreased by 44.4% year-over-year, from $32.18M to $17.88M.
- What is the long-term trend for Royalty Pharma's net income?
- Over 3 years (2021 to 2025), Royalty Pharma's net income has grown at a 7.7% compound annual growth rate (CAGR), from $619.73M to $773.95M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Royalty Pharma's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude